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Abstract: The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients
with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the
clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly
Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with
IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ฀45%
predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease,
and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward’s
minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival;
and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to
follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters
were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly
never smokers, DLCO ฀45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent
comorbidities, no smoking history, DLCO mostly ฀45%; and Cluster 3 (n = 434; 51.6%): median age 72
years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a
better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6%
in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between
all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis
identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
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The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-
capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical
presentation of these patients.
Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary
Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion
capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and
presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A
hierarchical agglomerative clustering algorithm was performed using Ward’s minimum variance
method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pul-
monary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in func-
tional class, 6-minute walking distance, cardiac biomarkers, and risk.
Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no
comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years,
98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3
(n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and
low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other
clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3
(unadjusted p < 0.001 for comparison between all groups).
The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified dis-
tinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
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Pulmonary arterial hypertension (PAH) consists of heter-
ogenous conditions that share a similar pulmonary arterial
vasculopathy and a common therapeutic approach. PAH
can be associated with well-defined diseases such as con-
nective tissue disease, HIV infection, liver disease, or con-
genital heart disease, but the most common form of PAH is
idiopathic (IPAH). A diagnosis of IPAH is made once the
presence of pre-capillary pulmonary hypertension (PH) has
been determined by right heart catheterization and other
forms of PH and PAH have been excluded.1
Originally, IPAH (formerly known as primary PH) was
described as a disease affecting primarily younger females
without typical risk factors for cardiopulmonary diseases.2
Contemporary registries from developing countries have
shown a similar pattern.3,4 However, more recent registries
from Europe and the US have demonstrated a change in the
demographics of patients diagnosed with IPAH character-
ized by increasing age and an accompanying surge in car-
diopulmonary comorbidities.5−9
Comprehensive phenotypic analysis of large cohorts of
patients diagnosed with IPAH have not yet been performed.
Here, we present data from a cluster analysis of patients
diagnosed with IPAH who have been enrolled in the Com-
parative, Prospective Registry of Newly Initiated Therapies
for Pulmonary Hypertension (COMPERA). Cluster analysis
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is a data-driven approach that groups subjects into so-called
clusters such that the subjects in each cluster are more simi-
lar to each other than to those in other clusters. It belongs to
the unsupervised statistical learning methods, which means
that it can be applied when groups are not known in
advance. Few cluster analyses have been performed in
patients with PH, but these analyses did not incorporate risk
factors for other cardiopulmonary diseases.10−12
The primary objective of this investigation was to iden-
tify clinical phenotypes of adult patients with IPAH from
COMPERA. As secondary objectives, responses to medical




Details of COMPERA (www.COMPERA.org; registered at
Clinicaltrials.gov under the identifier NCT01347216) have been
described previously.7,13−15 In brief, COMPERA is an ongoing web-
based PH registry launched in 2007 that collects baseline, follow-up,
and outcome data from patients who receive targeted therapies for
PH. Specialized centers from several European countries participate
(Austria, Belgium, Germany, Greece, Hungary, Italy, Latvia, Lithua-
nia, Netherlands, Slovakia, Switzerland, United Kingdom), with
about 80% of the enrolled patients coming from German PH centers.
Patients
Patients were selected from the COMPERA database using the
following criteria: (1) treatment-naive patients newly diagnosed
with IPAH between June 1, 2007 and November 11, 2019; (2)
mean pulmonary arterial pressure (mPAP) ≥25 mm Hg, pulmo-
nary arterial wedge pressure (PAWP) ≤15 mm Hg, and pulmonary
vascular resistance (PVR) >240 dyn¢s¢cm5 at the time of diagno-
sis; (3) complete data concerning the parameters selected for clus-
tering (described later); and (4) at least 1 follow-up visit available.
Patients with other forms of PH or PAH were excluded, as were
patients with hereditary or drug-associated PAH and patients
younger than 18 years at diagnosis.
Statistical analyses
Hierarchical agglomerative clustering was performed using
Ward’s minimum variance method as linkage criterion. For calcu-
lation of the pairwise dissimilarities between observations,
Gower’s formula was used, as it is able to deal with variables of
mixed type. The number of clusters was determined to be 3 based
on the clinical observations outlined in the introduction. Cluster
analysis requires complete data of all patients. The baseline
parameters considered in the cluster analysis were age (continu-
ous), sex (dichotomous), smoking history (dichotomous; never vs
current/former), diffusion capacity of the lung for carbon monox-
ide (DLCO) (dichotomous; <45% vs ≥45% of the predicted
value),16,17 and comorbidities (dichotomous; none vs at least 1 of
the pre-defined comorbidities: arterial hypertension, coronary
heart disease [here, the database just captured whether coronary
heart disease was present or not, without further details], diabetes
mellitus, and obesity defined by a body mass index [BMI]
≥30 kg/m2). Secondary cluster analyses were performed with the
same parameters but different cut-offs for the numbers of comor-
bidities, including modified Ambrisentan and Tadalafil in Patients
with Pulmonary Arterial Hypertension (AMBITION) trial criteria
based on <3 vs ≥3 comorbidities.18 The variables were selected
based on their assumed association with disease phenotypes.
Continuous data are presented as mean § SD or as median and
first and third quartile (Q1, Q3), categorical data as number and
percentage. Survival was evaluated using Kaplan-Meier analysis,
log-rank test, and Cox proportional hazards regression models to
adjust for age.
To compare the obtained clusters, Kruskal-Wallis tests and chi-
square tests were applied for continuous and categorical data,
respectively. If the p-value was < 0.05, Wilcoxon rank sum and
chi-square tests were performed to compare the clusters pairwise.
Because of the exploratory nature of this study, no adjustment for
multiple testing was made.
Response to PAH therapy was determined by changes from
baseline to first follow-up (>3 months after treatment initiation).
For 6-minute walking distance (6MWD), the difference in meters
between first follow-up and baseline measures were calculated.
For brain natriuretic peptide (BNP) and N-terminal fragment of
probrain natriuretic peptide (NT-proBNP), the change at follow-
up in percent of baseline was considered. Changes in functional
class (FC) and risk status were summarized in the categories
better, stable, and worse, referring to the status at follow-up com-
pared with baseline. Risk status was assessed by the Swedish/
COMPERA approach using non-invasive data15,19 using the cut-
off values suggested by the current European Society of Cardiol-
ogy/European Respiratory Society PH guidelines.20,21. All statisti-
cal analyses were performed using R version 3.5.2.
Results
Patients and clusters
A flow diagram showing patient selection from the COM-
PERA database is depicted in Figure 1. Of 2,276 patients with
IPAH, 841 (37.0%) patients met the inclusion criteria and
were eligible for this study. The baseline characteristics of
selected and non-selected patients were similar (Supplemen-
tary Table S1, available online at www.jhltonline.org).
The characteristics of the patients in the 3 clusters are
presented in Table 1. Cluster 1 consisted of 106 (12.6%)
patients with a median age of 45 years and a female to male
ratio of approximately 3:1. These patients had none of the
pre-specified risk factors for left heart disease. About one
third of the patients were former or current smokers with a
median of 16 pack years. Lung function was largely normal,
and all patients had a DLCO ≥45% of the predicted value.
Cluster 2 was formed of 301 (35.8%) patients. These
patients were almost exclusively (98%) females with a
median age of 75 years. None of these patients had a smok-
ing history, but almost all (94%) had at least 1 of the pre-
specified risk factors for left heart disease.
The largest cluster (Cluster 3; n = 434; 51.6%) was
formed by predominantly (72%) male patients with a
median age of 72 years. As in Cluster 2, most of the patients
(91%) in Cluster 3 had risk factors for left heart disease.
What discriminated the patients in Cluster 3 from those in
Cluster 2 was the male predominance, the high proportion
(79%) of patients with a smoking history (median: 33 pack
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years), and the large amount (53%) of patients with a
DLCO <45% of the predicted value.
When the cluster analysis was repeated based on the
presence of <3 vs ≥3 risk factors for left heart disease as
done in the AMBITION study,18,22 it was not possible to
obtain distinct phenotypes. Even when we used <2 vs ≥2
risk factors for left heart disease as discriminators, cluster
analysis did not discriminate well between phenotypes
(Supplementary Tables S3 and S4, Supplementary Figures
S1 and S2) online.
Clinical features at baseline
Besides the differences in age, sex, comorbidities, and
smoking pattern described previously, there were distinct
baseline features among the 3 clusters (Table 1 and
Supplementary Table S2 online). All 3 clusters were char-
acterized by severe pre-capillary PH. Pulmonary function
expressed as total lung capacity (TLC), forced vital capac-
ity (FVC), and forced expiratory volume in 1 second
(FEV1) was in the normal range in all 3 clusters but with
the lowest numbers in Cluster 3; patients in this cluster also
had lower arterial oxygen tension values than patients in
the 2 other clusters.
The proportion of patients with a history of atrial fibrilla-
tion was 8%, 36%, and 25%, respectively, in Clusters 1, 2,
and 3. When comparing baseline characteristics across clus-
ters, patients with a history of atrial fibrillation were older
and had a higher prevalence of comorbidities than patients
without atrial fibrillation (Supplementary Table S5) online.
PAH therapy and treatment response
Table 2 shows PAH treatments according to clusters.
Patients in Cluster 1 were treated predominantly with
phospodiesterase-5 inhibitors and/or endothelin receptor
antagonists. Combinations of PAH therapies were used in
38% of the patients within the first 3 months of diagnosis
(between 2007 and 2014, the proportion of patents receiv-
ing initial combination therapy in this cluster was 26.5%;
between 2015 and 2019, the corresponding figure was
49.0%). After 1 year, 63% of these patients were receiving
combination therapies. Patients in Clusters 2 and 3 were
predominantly treated with phospodiesterase-5 inhibitor
monotherapy, both at baseline and at follow-up. Combina-
tions of PAH drugs were used in 13% and 15% of the
patients in Cluster 2 and Cluster 3, respectively, at baseline
and in 28% and 39% of the patients in Cluster 2 and Cluster
3, respectively, at follow-up.
Treatment responses assessed by changes in 6MWD and
BNP/NT-proBNP from baseline to follow-up are shown in
Figure 2. The 6MWD increased by 85 § 87 m in Cluster 1,
by 20 § 73 m in Cluster 2, and by 37 § 78 m in Cluster 3.
BNP/NT-proBNP levels declined from baseline to follow-
up by a median of 54% (interquartile range [IQR]: 11% to
80%) in Cluster 1, by 6% (IQR: 46% to +39%) in Clus-
ter 2, and by 23% (IQR: -55 to +16%) in Cluster 3.
FC improved in 51% of patients in Cluster 1, remained
stable in 48%, and worsened in 1%. In Cluster 2, FC
improved in 33%, remained stable in 63%, and worsened in
4% of the patients. In Cluster 3, FC improved in 36%,
remained stable in 60%, and worsened in 4% of the patients.
Risk, as assessed by the Swedish/COMPERA approach,
improved substantially in Cluster 1 patients but to a much
lesser extent in Cluster 2 and Cluster 3 patients (Figure 3).
Survival
Survival rates at 1, 3, and 5 years in Cluster 1 were 93.7%,
88.4%, and 84.6%, respectively; 93.5%, 75.7%, and 59.2%,
Figure 1 STROBE diagram showing patient selection for the analysis.
*Patients could have had more than 1 reason for not being eligible for this study. COMPERA, Comparative, Prospective Registry of Newly
Initiated Therapies for Pulmonary Hypertension; DLCO, diffusion capacity of the lung for carbon monoxide; IPAH, idiopathic pulmonary
arterial hypertension; PAPm, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resis-
tance; STROBE, STrengthening the Reporting of OBservational studies in Epidemiology.
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respectively, in Cluster 2; and 90.0%, 61.9%, and 42.2%,
respectively, in Cluster 3 (Figure 4). The unadjusted differ-
ences between the groups were statistically significant (p <
0.0001). When adjusted for age, the differences between
Clusters 1 and 3 and Clusters 2 and 3 remained significant
(p = 0.005 and p < 0.001, respectively), whereas the sur-
vival difference between Clusters 1 and 2 was no longer sta-
tistically significant.
A sensitivity analysis including only patients without a
history of atrial fibrillation showed similar results
(Supplementary Table S6 and Supplementary Figure S3).
Discussion
This study confirms that the population of patients diag-
nosed with IPAH is heterogeneous. Our cluster analysis
Table 1 Patient Characteristics at the Time of IPAH Diagnosis
Characteristic Cluster 1n = 106 Cluster 2n = 301 Cluster 3n = 434 p-valuea Alln = 846
Age, years (median, Q1−Q3) 45 (31−61) 75 (68−80) 72 (64−78) <0.001 72 (61−78)
Female sex, n (%) 80 (76) 296 (98) 121 (28) <0.001 497 (59)
BMI, kg/m2 (mean § SD) 24.2 § 3.2 30.7 § 7.2 29.1 § 5.9 <0.001 29.1 § 6.5
Smoking habits
Former/current smokers, n (%) 33 (31) 0 (0) 343 (79) <0.001 376 (44)
Pack years (median, Q1−Q3) 16 (10−28) — 33 (20−50) <0.001 30 (15−50)
WHO FC <0.001
I/II, n (%) 20 (19) 20 (7) 25 (6) 65 (8)
III, n (%) 75 (72) 215 (72) 311 (76) 601 (74)
IV, n (%) 9 (9) 63 (21) 72 (18) 144 (18)
6MWD, m (mean § SD) 386 § 119 268 § 114 276 § 108 <0.001 287 § 118
BNP, ng/l (median, Q1−Q3) 129 (81−259) 206 (92−299) 278 (112−468) 0.183 206 (101−371)
NT-proBNP, ng/l (median, Q1−Q3) 1,313 (524−2,480) 1,579 (676−3,520) 1,835 (634−3,592) 0.065 1,614 (631−3,460)
Hemodynamics
RAP, mm Hg (mean § SD) 7 § 5 8 § 5 8 § 4 0.026 8 § 5
mPAP, mm Hg (mean § SD) 49 § 14 40 § 11 43 § 11 <0.001 42 § 12
PAWP, mm Hg (mean § SD) 8 § 3 10 § 3 9 § 4 <0.001 9 § 3
CI, l/min/m2 (mean § SD) 2.1 § 0.7 2.0 § 0.6 2.1 § 0.7 0.471 2.1 § 0.7
PVR, dyn¢s¢cm5 (mean § SD) 948 § 463 727 § 398 730 § 380 <0.001 756 § 404
SvO2, % (mean § SD) 64 § 10 64 § 8 62 § 8 <0.001 63 § 8
Pulmonary function and blood gases
TLC, % predicted (mean § SD) 99 § 16 93 § 17 92 § 17 <0.001 93 § 17
FVC, % predicted (mean § SD) 92 § 17 83 § 18 80 § 20 <0.001 82 § 20
FEV1, % predicted (mean § SD) 87 § 17 80 § 19 75 § 20 <0.001 78 § 19
DLCO, % predicted (mean § SD) 69 § 15 56 § 22 47 § 21 <0.001 53 § 22
DLCO <45% predicted, n (%) 0 (0) 101 (34) 231 (53) <0.001 332 (40)
paO2, mm Hg (mean § SD) 77 § 17 65 § 11 61 § 12 <0.001 65 § 14
paCO2, mm Hg (mean § SD) 33 § 4 36 § 6 36 § 7 <0.001 35 § 6
Comorbidities
Arterial hypertension, n (%) 0 (0) 251 (83) 320 (74) <0.001 571 (68)
Coronary heart disease, n (%) 0 (0) 58 (19) 153 (35) <0.001 211 (25)
Diabetes mellitus, n (%) 0 (0) 106 (35) 154 (36) <0.001 260 (31)
BMI ≥30 kg/m2, n (%) 0 (0) 149 (50) 170 (39) <0.001 319 (38)
At least 1 comorbidity 0 (0) 283 (94) 396 (91) <0.001 679 (81)
Number of comorbidities <0.001
0, n (%) 106 (100) 18 (6) 38 (9) 162 (19)
1, n (%) 0 (0) 93 (31) 138 (32) 231 (28)
2, n (%) 0 (0) 116 (38) 139 (32) 255 (30)
3, n (%) 0 (0) 57 (19) 95 (22) 152 (18)
4, n (%) 0 (0) 17 (6) 25 (6) 41 (5)
History of atrial fibrillation, n (%) 8 (8) 109 (36) 108 (25) <0.001 225 (27)
6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide; CI, cardiac index; DLCO, diffusion capacity of the lung for car-
bon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pul-
monary arterial pressure; NT-proBNP, N-terminal fragment of probrain natriuretic peptide; paCO2, arterial carbon dioxide tension; paO2, arterial oxygen
tension; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SvO2, mixed-venous oxygen saturation;
TLC, total lung capacity; WHO FC, World Health Organization Functional Class.
Categorical data are shown as n and % of the respective population. Continuous data are depicted as mean § SD or median (Q1−Q3).
aComparison of the 3 groups by Kruskal-Wallis test for continuous variables and chi-square test for binary variables. Detailed information on p-values
between each group can be obtained from the online supplement.
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identified 3 distinct cohorts: (1) patients with a classical
IPAH phenotype (Cluster 1) characterized by relatively
young age, female predominance, absence of pre-defined
risk factors for cardiopulmonary disease, and preserved
DLCO; (2) patients with a heart failure with preserved ejec-
tion fraction (HFpEF)-like phenotype (Cluster 2), that is,
mostly elderly women with abundant risk factors for left
heart disease but without a history of smoking, most of
them presenting with preserved DLCO; and (3) patients
with a cardiopulmonary phenotype (Cluster 3), consisting
of mostly elderly men with a history of smoking who pre-
sented with abundant risk factors for left heart disease but
also with low DLCO. Patients in the 3 clusters not only
differed in demographics and comorbidities but also
showed a different response to PAH therapy and different
survival rates. It remains unclear whether these differences
were related to the pulmonary vascular disease itself or to
other factors, such as different treatment strategies or
comorbidities.
Patients with the classical IPAH phenotype formed only
12.5% of our cohort. This low number resulted from our
strategy of identifying patients without pre-specified risk
factors for left heart disease. About 30% of these patients
had a history of tobacco smoking, which is in line with the
proportion of smokers in Europe23. The median number of
pack years was 16, making it unlikely that smoking had
contributed in a clinically relevant manner to the pulmonary
vasculopathy of these patients. Patients in Cluster 1 were
slightly older but otherwise comparable to the US National
Institutes of Health cohort of patients with primary PH
described in 1987.2 Compared with the other clusters,
patients in Cluster 1 were younger and presented with
higher levels of mPAP and PVR at baseline but showed the
best response to medical therapy and had the highest (unad-
justed) survival rates. However, when adjusted for age, the
survival difference between Clusters 1 and 2 was no longer
statistically significant.
Cluster 2 consisted almost exclusively of elderly women
with a median age of 75 years who had no smoking history
but multiple other risk factors for left heart disease. These
patients presented with an HFpEF phenotype,24,25 yet they
fulfilled the diagnostic criteria of IPAH including the pres-
ence of pre-capillary PH with a PAWP of 10 § 3 mm Hg.
Still, it is likely that many of these patients pathogenetically
had Group 2 PH, that is, PH because of left heart disease
rather than classical IPAH. It is well known that PAWP
at rest can be normal in these patients.26,27 Data on hemody-
namics during exercise or volume challenge that might
provide additional diagnostic information25) were not
available.
Attempting to distinguish between patients with IPAH
with a classical phenotype and those with an HFpEF pheno-
type, the AMBITION study introduced an arbitrary cut-off
of <3 vs ≥3 pre-specified comorbidities.18,22 When apply-
ing this strategy to this cluster analysis, we lost the pheno-
typic discrimination between the clusters. Based on these
data, we doubt that the AMBITION strategy is well suited
to distinguish patients with a classical IPAH phenotype
from those with a left heart disease phenotype. Our cluster
analysis yielded a clean population of patients with classical
IPAH only when we distinguished between patients with
or without any risk factors for left heart disease. These
observations may be considered when planning future clini-
cal trials.
The third and largest (51.6%) cluster of patients was also
the most complex; in terms of age, the patients were compa-
rable to Cluster 2 (median age: 72 vs 75 years). The patients
in Cluster 3 also had abundant risk factors for left heart dis-
ease. However, in contrast to the 2 other clusters, patients
in Cluster 3 were predominantly male, and most of them
had a history of smoking. Although lung function measured
by TLC, FVC, and FEV1 was normal, DLCO and arterial
oxygen tension were lower than in the 2 other clusters.
Similar to the patients in Cluster 2, patients in Cluster 3 ful-
filled the current diagnostic criteria for IPAH. However,
these patients appeared to have at least 2 additional compo-
nents contributing to the development of PH, that is, an
abundance of risk factors for left heart disease similar to
Cluster 2 with an additional smoking-associated pulmonary
vasculopathy.
The concept of a smoking-associated pulmonary vascul-
opathy is relatively new. In mice exposed to tobacco smoke,
Table 2 PAH Therapies According to Clusters
Therapy Cluster 1n = 106 Cluster 2n = 306 Cluster 3n = 434 Alln = 846
PAH medication within 3 months after diagnosis
Calcium channel blocker monotherapy, n (%) 16 (16) 3 (1) 5 (1) 24 (3)
PDE5i or sGC stimulators, n (%) 76 (76) 257 (90) 358 (86) 691 (86)
ERA, n (%) 43 (43) 59 (21) 108 (26) 210 (26)
PCA, n (%) 5 (5) 7 (2) 6 (1) 18 (2)
Combination therapies, n (%) 38 (38) 38 (13) 63 (15) 139 (17)
PAH medication at 1 year after diagnosis
Calcium channel blocker monotherapy, n (%) 17 (16) 3 (1) 5 (1) 25 (3)
PDE5i or sGC stimulators, n (%) 63 (81) 193 (86) 277 (86) 533 (85)
ERA, n (%) 50 (64) 74 (33) 144 (45) 268 (43)
PCA, n (%) 9 (12) 16 (7) 18 (6) 43 (7)
Combination therapies, n (%) 49 (63) 62 (28) 125 (39) 236 (38)
ERA, endothelin receptor antagonists; PAH, pulmonary arterial hypertension; PCA, prostacyclin analog (including prostacyclin receptor agonists);
PDE5i, phosphodiesterase-5 inhibitor; sGC, soluble guanylate cyclase.
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a loss of pulmonary capillaries because of apoptosis pre-
cedes the development of emphysematous changes.28 It has
been proposed that a similar pulmonary small vessel pathol-
ogy may develop in patients with a history of smoking.16, 29
−31 Apparently, this pulmonary vasculopathy can develop
in patients with or without clinical and radiological signs of
parenchymal lung disease.29 Patients in Cluster 3 had a par-
ticularly poor survival, which is consistent with previous
reports on patients with IPAH and low DLCO.16,29,31 Fur-
ther studies are needed to delineate the mechanisms under-
lying the survival differences between the clusters.
PAH treatments varied between the clusters. Combina-
tions of PAH drugs were used much more frequently in
Cluster 1 than in the 2 other clusters. Patients receiving cal-
cium channel blocker monotherapy were found almost
exclusively in this cluster. Treatment response in terms of
improving 6MWD, FC, BNP/NT-proBNP, and risk was
seen in all clusters, but treatment effects were considerably
more pronounced in Cluster 1 than in the 2 other clusters. It
is unclear whether this was due to the more aggressive treat-
ment approach or to a better responsiveness of these
patients.
Our study has potential implications. First, it confirms
and extends previous reports suggesting that there are dif-
ferent phenotypes among patients diagnosed with IPAH.
Second, our data show that—at least in the participating
European countries—most patients diagnosed with IPAH
are phenotypically different from the patients originally
described.2 Third, while acknowledging that the different
survival rates may reflect the impact of age and
Figure 2 Changes from baseline to first follow-up in (a) 6MWD (difference in m) and (b) BNP/NT-proBNP (%) (20 outliers > 200% in
Clusters 2 and 3 are not depicted). 6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP, N-terminal fragment of
probrain natriuretic peptide.
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comorbidities, our findings raise the hypothesis that distinct
etiologies and different pathophysiological mechanisms
contributed to the pulmonary vascular disease in the
patients under study.
Our study has strengths and limitations. The main
strength is the large cohort of eligible patients; further
strengths are the real-world setting, the prospective and
multicenter data acquisition, and the long follow-up period.
It is uncertain whether all patients were correctly classified,
but they all fulfilled the current diagnostic criteria for
IPAH. Although COMPERA is a European registry with
participation from 12 countries, about 80% of the patients
were enrolled from Germany, generating potential bias,
starting with the age and demographics of the patients.
Given that the data were captured over a 12-year period,
PAH treatments may not always reflect the contemporary
approach, which explains the relatively infrequent use of
combination therapy. Further limitations include the inher-
ent weaknesses of registries such as missing values and a
limited data set, making it difficult to obtain additional data
on relevant variables such as comorbidities, echocardiogra-
phy, or chest imaging. It is unknown if the patients with
severely impaired DLCO had radiological signs of paren-
chymal lung disease. Still, pulmonary function measured
by TLC, FVC, and FEV1 was preserved in these patients,
and a recent study by Lewis et al30 has shown that patients
with this phenotype may present with normal or near-nor-
mal chest computer tomography findings.31
Furthermore, some limitations related to the cluster
approach require consideration. The methodological postu-
late of cluster analysis is not to have missing data. This cri-
terion was met by only 37% of the patients with IPAH
enrolled into COMPERA, which may have resulted in
selection bias. In addition, although cluster analysis does
not require an a priori hypothesis, the variables of interest
have to be selected in advance, which implies a kind of
assumption, in particular, as the number of variables con-
sidered in this cluster analysis was relatively low. With
different variables, the segmentation might have been dif-
ferent.
In conclusion, our cluster analysis yielded 3 distinct
IPAH phenotypes. The smallest cohort were patients with
classical IPAH, that is, predominantly females of younger
age without cardiovascular risk factors. The next largest
cohort were older women without a history of smoking but
with abundant risk factors for left heart disease. The largest
cohort were older patients, predominantly males, most of
whom had a history of smoking. Among the 3 clusters,
patients with classical IPAH had the best survival, whereas
the survival of the latter group of patients was particularly
poor. It is likely that the pathogenetic mechanisms leading
to PAH differ among these 3 cohorts, and our data indicate
that the same may be true for the response to PAH therapy.
Figure 3 Risk as determined by the Swedish/COMPERA approach at baseline and follow-up in the 3 clusters. COMPERA, Compara-
tive, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension.
Figure 4 Kaplan-Meier survival estimates according to clusters.
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